Get the content you want anytime you want.

Society of Infectious Diseases Pharmacists

Society of Infectious Diseases Pharmacists
Founded in 1990, the Society of Infectious Diseases Pharmacists (SIDP) is an association of pharmacists and allied healthcare professionals dedicated to promoting the appropriate use of antimicrobial agents.

Latest Partner Content

Alternative Antiretroviral Medication Delivery Systems Emerge to Treat, Prevent HIV Infection
Novel modes of delivery are imperative to improve HIV suppression and prevent transmission.
Teaching Old Dogs New Tricks: Make the Most of Twitter to Boost ID Education, Engagement, and Advocacy
Infectious diseases clinicians turn to Twitter as a tool for education and collaboration.
Entering the Ring: Oral Vancomycin Versus Metronidazole for <i>C difficile</i> Infection and the Risk of Vancomycin-Resistant <i>Enterococcus</i>
In 2017, a guideline update stripped metronidazole of its first-line therapy designation and crowned oral vancomycin as initial therapy for all C difficile infection cases.
Changes in Therapy Recommendations in the 2019 ATS/IDSA Guidelines for Community-Acquired Pneumonia
This article highlights some key updates to the antimicrobial therapy recommendations in the updated community-acquired pneumonia guidelines.
By stopping unnecessary antibiotics before they start, clinicians can avoid unnecessary harm to the patient and the population. 
Evaluating the Role of New Beta-Lactam Agents for Uncommon Pathogens
Novel β-lactam/β-lactamase inhibitor combinations and cefiderocol may play a part in the treatment of infections caused by Stenotrophomonas maltophilia, Achromobacter xylosoxidans, and Burkholderia cepacia complex. 
Investigational Treatments for <i>Clostridioides difficile</i> Infection
The high recurrence rates of Clostridioides difficile infection highlight the need for novel agents with unique mechanisms of action for treating the infection. 
What's New From the CLSI Subcommittee on Antimicrobial Susceptibility Testing
Updates include novel and revised breakpoints for azithromycin, polymyxins, daptomycin, and cefiderocol.
Is there a cure? How long until we find it? And will it work for the majority of people living with HIV?